Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Double-Blind, Placebo-Controlled, Randomized Efficacy, Safety and Tolerability Study of Lymfactin in Combination With Surgical Lymph Node Transfer To Patients With Secondary Lymphedema Associated With the Treatment of Breast Cancer

NCT03658967 is registered in ClinicalTrials.gov with Herantis Pharma Plc. as lead sponsor.

NCT NCT03658967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03658967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Double-Blind, Placebo-Controlled, Randomized Efficacy, Safety and Tolerability Study of Lymfactin in Combination With Surgical Lymph Node Transfer To Patients With Secondary Lymphedema Associated With the Treatment of Breast Cancer
Lead sponsor
Herantis Pharma Plc.
Phase
Phase 2
Overall status
Completed
Start date
June 7, 2018
Completion date
October 23, 2024
Enrollment
39 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

secondary lymphedema